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Abstract: 
The Wnt signalling pathway in beta-cells has been linked to the development of type 2 
diabetes. Investigating the impact of a non-canonical Wnt ligand, Wnt4, on beta-cell function 
we found that in INS-1 cells, Wnt4 was able to completely block Wnt3a stimulated cell 
growth and insulin secretion. However, despite high levels of Wnt4 protein being detected in 
INS-1 cells, reducing the expression of Wnt4 had no impact on cell growth or Wnt3a 
signalling. As such, the role of the endogenously expressed Wnt4 in beta-cells is unclear, 
but the data showing that Wnt4 can act as a negative regulator of canonical Wnt signalling in 
beta-cells suggests that this pathway could be a potential target for modulating beta-cell 
function.  
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Introduction 
Wnt signalling was first proposed to be important in the pathogenesis of type 2 diabetes 
when variants in the transcription factor TCF7L2, a key component of the Wnt pathway, were 
discovered as strong risk factors for this illness [1]. Subsequent studies implicated β-cell 
dysfunction as the underlying cause of diabetes in patients with the TCF7L2 risk variant [2-5] 
and have suggested that Wnt signalling plays an important role in both pancreatic 
development and in the function of mature pancreatic islets [6]. The activation of the 
canonical Wnt pathway, by ligands such as Wnt3a, has been of particular interest as it can 
increase β-cell proliferation, decrease apoptosis and improve glucose stimulated insulin 
secretion [6-12]. However there is now increasing evidence that non-canonical Wnt ligands 
such as Wnt4 can antagonise the signalling mediated by Wnt3a and may play an equally 
important role in β-cell function [13-15].  
The Wnt signalling pathway is mediated by Wnt ligands binding to cell surface receptors 
known as Frizzled (Fzd) molecules. Downstream signalling from these receptors appears to 
follow distinct pathways [16, 17]. The best characterised of these is the “canonical pathway” 
which regulates gene transcription by controlling the protein levels and cellular localisation of 
β-catenin [18]. In the nucleus β-catenin can act as a transcription factor (along with its co-
factors TCF/LEF) to promote gene transcription of effectors of Wnt signalling, such as c-myc 
and cyclin D2. In contrast, the non-canonical pathways, such as those stimulated by Wnt4 
are β-catenin independent and have been shown to antagonise the canonical Wnt pathway 
in several cell types [13, 14, 19-21].  
Our previously published data [22] showed that most Wnt ligands were either not expressed 
(including the canonical Wnt ligand, Wnt3a) or were present at only very low levels in a β-
cell line. The exception was Wnt4 which was expressed at levels more than 10 fold higher 
than any other Wnt ligand [22]. In addition Wnt4 protein has been detected in adult mouse 
islets but not in several other tissues including liver and kidney [14]. Wnt4 has also been 
found to be upregulated in the islets of two different insulin resistant mouse strains [14] and 
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in the islets of patients with type 2 diabetes [23] suggesting that Wnt4 may have islet specific 
functions in adults and a possible role in the development of diabetes.  
In this paper we set out to determine the function of Wnt4 in pancreatic β-cells. Our data 
shows that the endogenous Wnt4 present in β-cells is not secreted and has no impact on β-
cell growth or β-catenin levels. In contrast treatment of β-cells with exogenous Wnt4 is able 
to antagonise canonical Wnt signalling leading to inhibition of Wnt3a stimulated β-cell 
proliferation and insulin secretion. 
 
 
Material and Methods: 
Immunohistochemistry  
Paraffin embedded human pancreatic sections were obtained from two different healthy non 
diabetic cases (60 year old male (202/75) and 76 year old female (329/66)) from the Exeter 
Archival Diabetes Biobank. All samples were studied with ethical approval. 
Immunohistochemisty was carried out as previously described [24]. Sections were incubated 
with primary Wnt4 antibody (AF745; RnD systems; 1/25) before incubation with flurochrome-
conjugated secondary antibody (Goat anti-rabbit Fluor488) for 1hr (room temperature).  
Tissue sections were then incubated with insulin (A0564; Dako; 1/600) and glucagon 
(AB10988; Abcam; 1/2000) primary antibodies for 1hr followed by flurochrome-conjugated 
secondary antibody (Goat anti-guinea pig Fluor647 and Goat anti-mouse Fluor568 1/400) 
and DAPI (1/1000) for 1 hour. Immunofluorescence image collection and processing was 
achieved using a Leica DM4000 B LED upright fluorescence microscope and Leica Image 
analysis software (LAS AF). 
Cell culture: 
INS-1 cells were grown in RPMI 1640 medium containing 11mM glucose, supplemented with 
10% (v/v) foetal bovine serum, 2mM L-glutamine, 100µg/ml penicillin, 100µg/ml streptomycin 
and 50mM β-mercaptoethanol. 
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To determine cell growth, cells were treated with test ligands in 1% (v/v) serum containing 
media and counted using a haemocytometer.  
Wnt4 siRNA of INS-1 cells 
INS-1 cells were transfected with 10nM silencer select siRNA Wnt4 s136596 (Lifetech) using 
lipofectamine RNAi MAX (Lifetech) diluted in optimem (Gibco) media. A scrambled siRNA 
was used as a negative control. 
Wnt4 ELISA 
INS-1 cells were cultured for 72hrs before lysis in PBS by repeated freeze thawing. The 
media from the cultured cells was concentrated approximately ten fold using an Amico Ultra-
15 centrifugal device. Levels of Wnt4 were measured using a Cusabio Wnt4 rat ELISA 
according to the manufacturer’s instructions.  
Western blotting 
Whole cell lysates from INS-1 cells were prepared as previously described [25]. Nuclear and 
cytoplasmic protein fractions were separated using a nuclear and cytoplasmic extraction kit 
(Pierce) according to the manufacturer’s instructions. The membrane protein fraction was 
separated using differential centrifugation. INS-1 cells were lysed in ice cold homogenising 
buffer (HB; 20mM HEPES pH 7.4, 1µM EDTA, 250mM sucrose with the addition of protease 
and phosphatase inhibitors) and homogenised before two consecutive centrifugation steps 
at 1000g for 10 minutes at 4°C to sediment the nucl ei and cell debris. The remaining 
supernatant was centrifuged at 21,000g for 10 minutes at 4°C and the supernatant 
containing the cytoplasmic fraction was removed. The remaining pellet containing enriched 
membrane fraction was resuspended in HB and centrifuged at 21,000g for 10 minutes at 
4°C. The purified enriched pellet was resuspended i n RIPA buffer (50mM Tris  pH 7.4, 
150mM NaCl, 1% (v/v) Triton-X-100, 1% sodium deoxycholate (w/v), 0.1% SDS (v/v), 1mM 
EDTA with the addition of protease inhibitor and phosphatase inhibitors).  
Protein lysates were used in western blotting (previously described [25]) using the following 
primary antibodies and concentrations: Wnt4 (M70; Santa Cruz) 1 in 1000, Total β-catenin 
(05-613; Millipore) 1 in 1000, Active β-catenin (3024DP; Symansis) 1 in 1000,  Histone H3 
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(D1H2; NEB) 1 in 5000, Tubulin (Ab4074; Abcam) 1 in 5000, Sodium Potassium ATPase 
(Ab7671; Abcam) 1 in 2500. Protein levels were quantified using image J 
(http://imagej.nih.gov/ij/).  
PCR 
RNA was isolated from INS-1 cells using trizol reagent. 1µg of RNA was used in a one-step 
RT reaction (Applied Biosciences) to produce cDNA for use in qRT-PCR; amplified by SYBR 
Green PCR master mix (Applied Biosystems) and analyzed on an ABI PRISM 7900 
sequence detection system (Applied Biosystems). Primer sequences are available on 
request.  
Glucose stimulated insulin secretion 
To measure insulin secretion, INS-1 cells were incubated in Krebs-Ringer Bicarbonate buffer 
(KRB; 125mM NaCl, 4.74mM KCl, 1mM CaCl2, 1.2mM KH2PO4, 1.2mM MgSO4, 5mM 
NaHCO3, 25mM Hepes, pH 7.4 + 0.1% (w/v) BSA) containing 2.8mM glucose for 2 hours to 
reduce insulin secretion to basal glucose levels. This was followed by stimulation of the cells 
with the required treatments (in KRB) for 1 hour. Media was sampled for measurement of 
insulin by radioimmunoassay (Linco). Insulin secretion was normalised to the protein content 
of each well.  
Statistical analysis 
Data is presented as mean±SEM of treated samples compared to the untreated control. 
Significant differences between treatment and control values were determined by ANOVA 
followed by a Mann-Whitney test and Kruskal-wallis test. P values <0.05 were considered 
significant. 
 
Results: 
Functional impact of Wnt4 on β-cell growth and insulin secretion 
To investigate the functional impact of Wnt4 on beta-cells, INS-1 cells were treated with 
Wnt4 alone or in combination with Wnt3a and the impact on cell growth and insulin secretion 
measured. As expected, Wnt3a caused an increase in cell proliferation (Fig 1A) and 
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increased insulin secretion stimulated by high glucose levels (Fig 1B). Wnt4 alone however 
had no impact on these parameters, but was able to completely block Wnt3a stimulated 
increases in cell growth and insulin secretion (Fig 1A+B), showing that Wnt4 is able to 
functionally inhibit the actions of Wnt3a.  
Wnt4 mediated modulation of the canonical Wnt signalling pathway 
We next sought to determine the mechanism by which Wnt4 can inhibit Wnt3a actions in β-
cells. Stimulation of canonical Wnt signalling is characterised by the stabilisation of β-catenin 
protein due to inhibition of phosphorylation on two key sites (Ser37 and Thr41) by GSK3β. 
This hypo-phosphorylated form of β-catenin is referred to as ‘active’ β-catenin and is used as 
a marker of activation of the canonical pathway [6, 18]. In these experiments we have used 
two antibodies, one which recognises the hypo-phosphorylated form (referred to as ‘active’) 
and another that will detect all β-catenin protein regardless of its phosphorylated state 
(referred to as 'total’). 
As expected, treatment of INS-1 cells with Wnt3a caused an increase in the levels of both 
total and active β-catenin protein in the cytoplasmic and nuclear cell protein fractions (Fig 
1C+D). In contrast, treatment of INS-1 cells with Wnt4 didn’t increase protein levels of active 
β-catenin, but surprisingly did increase protein levels of total β-catenin in both cytoplasmic 
and nuclear fractions (Fig 1C+D). When INS-1 cells were treated with a combination of 
Wnt3a and Wnt4, Wnt3a mediated increases in cytoplasmic and nuclear active β-catenin 
were prevented by Wnt4 (Fig 1C+D) despite the continued presence of elevated total β-
catenin protein levels (Fig 1C+D).  
mRNA levels of β-catenin were also measured in INS-1 cells treated with Wnt3a and Wnt4. 
No changes in β-catenin mRNA expression were detected with either ligand alone or in 
combination (Fig 2A), suggesting that, as expected from the mechanism of the Wnt 
signalling pathway, any changes in protein levels of β-catenin caused by Wnt3a or Wnt4 
were not due to changes in gene expression.  
To test the idea that Wnt4 acts as a receptor antagonist of Wnt3a [14], cells were treated 
with the specific GSK3β inhibitor, 1-AKP to activate the Wnt signalling pathway downstream 
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of the Wnt3a receptor. Wnt4 was able to inhibit the increase in active β-catenin protein 
stimulated by 1-AKP (Fig 2B), suggesting that inhibition of Wnt3a mediated signalling by 
Wnt4 is not due to antagonism at the receptor level. 
Wnt4 has previously been shown to increase levels of β-catenin in the plasma membrane, 
suggesting that this might be a mechanism by which it could antagonise canonical Wnt 
signalling [21]. We investigated this theory and found that both Wnt3a and Wnt4 increased 
incorporation of β-catenin into the cell membranes, with no additive effect when both ligands 
were used in combination (Fig 2C).  
To determine if Wnt4 prevents Wnt3a stimulated cell growth through inhibition of β-catenin 
mediated gene transcription, mRNA levels of cyclin D2, a key target gene of canonical Wnt 
signalling, was measured. As expected treatment of INS-1 cells with Wnt3a increased levels 
of cyclin D2 mRNA. Unexpectedly however treatment with Wnt4 alone had a similar effect 
and did not prevent the Wnt3a stimulated increases in cyclin D2 expression (Fig 2D).  
Wnt4 expression and localisation: 
Having shown that β-cells can respond to exogenous treatment with Wnt4 we sought to 
determine the potential source of this ligand using immunohistochemistry in human islet 
sections. In agreement with Lee et al [23] we found strong expression of Wnt4 in α-cells (Fig 
3). However there was also staining for Wnt4 detectable at a lower intensity throughout the 
islet in insulin positive cells. These data suggest that in islets Wnt4 is expressed in both α 
and β-cells, with higher levels detected in α-cells.  
To determine if the Wnt4 detected in the β-cells has a functional role we reduced levels of 
Wnt4 in INS-1 cells using Wnt4 specific siRNA (Fig 4A). This reduction of Wnt4 protein didn't 
cause any change in the basal rate of cell growth (Fig 4B). In addition β-cells with reduced 
Wnt4 expression didn't show any enhancement in Wnt3a mediated increases in active β-
catenin levels when treated with Wnt ligands (Fig 4C), suggesting that endogenous Wnt4 
doesn't moderate the signalling activity stimulated by exogenous sources of Wnt3a.  
To establish whether Wnt4 is secreted from β-cells we measured Wnt4 in the culture media 
of INS-1 cells. Despite Wnt4 protein being detectable in the cell lysates, only very low levels 
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of Wnt4 were detectable in the cell media, suggesting that Wnt4 is not secreted by INS-1 
cells (Fig 4D).  
 
Discussion: 
There is considerable interest in the action of Wnt signalling in modulating β-cell growth and 
function, with the implication that changes in this pathway may be causative in the on-set of 
β-cell dysfunction that occurs in type 2 diabetes. In this paper we present unique functional 
data showing that Wnt4 is able to inhibit Wnt3a stimulated increases in β-cell growth and 
glucose stimulated insulin secretion.  
Interestingly previous studies have suggested that canonical Wnt signalling is not active in 
mature islets [14, 23]. It seems plausible that the lack of activity may be due to high levels of 
Wnt4 present in pancreatic islets inhibiting canonical Wnt signalling. Expression of Wnt4 
could potentially be important to maintain β-cell phenotype and prevent dysregulated 
increases in proliferation and insulin secretion by suppressing the activation of canonical 
Wnt signalling. This correlates with a recent publication in which an effector of a non-
canonical Wnt signalling pathway was found to be a marker of mature non-proliferating β-
cells [26].  
Experiments in this paper show that Wnt4 is highly expressed in human α-cells, with lower 
levels detected in β-cells, raising the possibility that β-cells may be exposed to Wnt4 from 
both exogenous and endogenous sources in the islets.  Our data shows that β-cells are 
capable of responding to exogenously applied purified recombinant Wnt4 protein as 
treatment of INS-1 cells with recombinant Wnt4 protein was able to inhibit increases in cell 
growth and insulin secretion mediated by Wnt3a. However when endogenous levels of Wnt4 
were reduced in the INS-1 cells lines, no impact on cell growth or Wnt signalling activation 
was measurable. There was also no change in cell growth rates of INS-1 cells with reduced 
Wnt4 expression. This finding differs from data presented by Heller et al (2011) [13] who 
also used Wnt4 siRNA in INS-1 cells, but found a decrease in cell growth. This difference 
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may be due to differing levels of knockdown or Wnt4 or different detection methods of cell 
proliferation.  
In addition we found that cells with reduced levels of Wnt4 protein did not have an increased 
response to treatment with Wnt3a when measuring increases in active β-catenin levels. This 
suggests that endogenously expressed Wnt4 in β-cells does not have a role in regulating β-
cell function and correlates with the data showing that Wnt4 is not secreted by INS-1 cells. 
Evidence suggests that Wnt4 would need to be secreted from the cells to activate cell 
signalling as the frizzled receptors are cell surface receptors and there are no reports to 
suggest an intracellular role of any Wnt ligands. However an in vivo exogenous source of 
Wnt4 acting on β-cells has yet to be proven. The high levels of Wnt4 expressed in α-cells, 
reported here and by others [23] points to an intra islet source of Wnt4. However a recent 
paper suggests that Wnt ligands secreted by adipose and muscle tissue can impact β-cell 
function [15].  
Previous reports have proposed various mechanisms by which Wnt4 may antagonise the 
canonical Wnt signalling pathway. One of these is that Wnt4 may act as a receptor 
antagonist to Wnt3a preventing Wnt3a activation of target cell surface receptors [14]. The 
results presented here show that Wnt4 is able to inhibit increases in active β-catenin levels 
mediated by the specific GSK3β inhibitor 1-AKP. This would suggest that Wnt4 is able to 
inhibit the canonical Wnt pathway at or downstream of GSK3β, rather than acting as a 
receptor antagonist.  Another possibility is that Wnt4 can increase β-catenin incorporation in 
adhesion junctions in the cell membrane [21] thus inhibiting canonical Wnt signalling by 
reducing the pool of β-catenin available for mediating gene transcription. We find that both 
Wnt3a and Wnt4 increase levels of β-catenin protein in the membrane fraction in INS-1 cells, 
with no further increase when cells are treated with both ligands together. This suggests 
increased incorporation of β-catenin at the adhesion junctions is not the mechanism by 
which Wnt4 inhibits Wnt3a mediated signalling.  
As expected from an inhibitor of the canonical Wnt signalling pathway we find that Wnt4 is 
able to inhibit the Wnt3a mediated increase in the hypo-phosphorylated (‘active’) form of β-
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catenin increased levels. Unexpectedly though for a proposed ‘non-canonical’ Wnt ligand 
Wnt4 itself lead to increased levels of ‘total’ β-catenin throughout the cell including the 
nucleus, cytoplasm and membrane. Under normal physiological conditions GSK3β 
phosphorylated β-catenin is rapidly degraded in the proteasome ensuring that cytoplasmic β-
catenin proteins levels remain low [27]. Wnt4 treatment did not increase the expression of 
the β-catenin mRNA suggesting that increased β-catenin protein levels are due to reduced 
proteasomal degradation rather than increased gene transcription. As Wnt4 did not increase 
levels of ‘active’ β-catenin, the increased β-catenin seen with Wnt4 is presumably still 
phosphorylated by GSK3β, suggest that Wnt4 may disrupt the ubiquitin proteasome pathway 
or stabilise β-catenin by phosphorylating the protein on a different residue. This GSK3β 
independent stabilisation of β-catenin has recently been described in tumour cells in 
response to unsaturated fatty acids in [28]. 
In the nucleus β-catenin acts, in combination with tcf/lef, as a transcription factor leading to 
increased transcription of β-catenin sensitive genes, such as cyclin D2. Interestingly we 
found that Wnt4, despite leading to decreases in active β-catenin in the nucleus, wasn’t able 
to prevent Wnt3a activation of cyclin D2. More surprisingly, Wnt4 itself was able to increase 
expression of cyclin D2 in β-cells, presumably due to its ability to increase levels of total β-
catenin in the nucleus. These observations imply that in addition to Wnt4 preventing 
increases in active β-catenin levels, it may also be able to act downstream of β-catenin 
mediated gene transcription to prevent Wnt3a mediated cell growth and insulin secretion.  
In conclusion the present results provide strong evidence that Wnt4 is able to functionally 
inhibit the actions of canonical Wnt signalling in pancreatic β-cells, leading to the inhibition of 
Wnt3a mediated increases in cell growth and insulin secretion. As such given the strong link 
of canonical Wnt signalling with diabetes on-set we suggest that modulation of Wnt4 protein 
expression in islets or targeting Wnt4 signalling pathways may represent a potential new 
target for the treatment of diabetes.  
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Figure Legends: 
Figure 1. Functional effects of Wnt4 on INS-1 cells.  
A: INS-1 cells were treated with 10ng/ml of Wnt3, Wnt4 or Wnt3a + Wnt4. Cells were 
retreated every 24hrs. After 72hrs of treatment cell numbers were determined by vital dye 
staining. B: INS-1 cells were pretreated for 24hrs with 10ng/ml of Wnt3a, Wnt4 or 
Wnt3a+Wnt4. Cells were then incubated for 2hrs at 2.8mM glucose before 1hr stimulation 
with 5.6 or 16.7mM glucose media, all in the continued presence of the Wnt ligands. The 
media was then sampled for use in a radioimmunoassay to measure insulin secretion.  
INS-1 cells were treated with 10ng/ml of Wnt3, Wnt4 or Wnt3a + Wnt4 for 24hrs before 
extraction of: C; cytoplasmic or D; nuclear protein for use in western blotting. Antibodies that 
recognise either total levels (total) or only the hypo-phosphorylated (active) form of beta-
catenin were used. Expression levels were quantified and normalised to tubulin (C) or 
histone H3 (D) expression levels.  
Figure 2: Wnt4 regulation of β-catenin expression and localisation.   
A INS-1 cells were treated with 10ng/ml of Wnt3, Wnt4 or Wnt3a + Wnt4 for 24hrs before 
extraction of mRNA for PCR. The mRNA was converted to cDNA and used in qRT-PCR to 
measure β-catenin mRNA levels. The results are normalised to two housekeeping genes 
(GAPDH and HPRT). Results are expressed as mean ± SEM.  
B: INS-1 cells were treated with either 5µM 1-AKP, 10ng/ml Wnt4 or 5µM 1-AKP and 
10ng/ml Wnt4 for 24hrs and the whole cell protein extracted. Active and total β-catenin 
levels were measured by western blotting and normalised to tubulin. Data shown as mean 
values ± SEM, n=3 * p<0.05 compared to the control.  
C: INS-1 cells were treated with Wnt3a, Wnt4 or Wnt3a and Wnt4 (10ng/ml) for 24hrs and 
the membrane fraction extracted. Total β-catenin levels were measured by western blotting 
and normalised to sodium potassium ATPase. Data shown as mean values ± SEM, n=3 * 
p<0.05 compared to the control. 
D: INS-1 cells were treated with Wnt3a, Wnt4 or Wnt3a and Wnt4 (10ng/ml) for 24hrs and 
the mRNA extracted. The mRNA was converted to cDNA and used in qRT-PCR to detect 
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cyclin D2 mRNA levels. The results are normalised to two housekeeping genes (GAPDH 
and HPRT) and expressed relative to the control. Data presented as the mean values ± 
SEM. n=3. **p<0.01 compared to the control 
 
Figure 3: Expression of Wnt4 in human islets  
Human pancreatic sections were incubated with antibodies against A: insulin 1/600 for 1hr 
(light blue) B: Wnt4 (AF475) overnight 1/25 (red) and C: glucagon 1/2000 for 1hr (green). 
Nuclei were stained with DAPI 1/1000 (blue). Following primary antibody incubation the 
tissue was incubated with the appropriate secondary antibody 1/400 for 1hr. E: Wnt4 
(AF475) Glucagon, insulin and dapi signals are overlaid. Scale bars = 25µm 
 
Figure 4. Function of exogenously expressed Wnt4 in INS-1 cells.  
A: Protein was extracted from INS-1 cells transfected with siRNA specific to Wnt4 or a 
scrambled control. Wnt4 protein expression was measured by western blotting and 
normalised to tubulin. Data shown as mean values ± SEM. ** p<0.001 compared to the 
scrambled control, n=3 
B: siRNA Wnt4 and scrambled control INS-1 cells were grown in 6 well plates for 72hrs and 
the total cell number counted and expressed as a fold increase over the number of cells 
seeded. Data shown as mean values ± SEM. n=3   
C: Scrambled siRNA and Wnt4 siRNA INS-1 cells were treated for 24hrs with Wnt3a 
(10ng/ml) and the whole cell protein extracted. Active and total β-catenin protein levels were 
measured by western blotting and normalised to tubulin. Data shown as mean values ± 
SEM. * p<0.01 n=3  
D: INS-1 cells were cultured for 72hrs before the protein was extracted and cell media 
removed for measurement of Wnt4 by ELISA. Data shown as mean values ± SEM. n=3. 
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• Wnt4 prevents Wnt3a from increasing growth and insulin secretion in β-cells 
• Wnt4 inhibits canonical Wnt signalling despite increasing total β-catenin levels  
• Exogenously expressed Wnt4 in β-cells has no impact on canonical Wnt signalling 
